UI
The startup develops lipid nanoparticles (LNPs) that specifically target myeloid cells, enabling the direct delivery of therapeutic agents to macrophages and dendritic cells. This technology facilitates the development of treatments for cancer, autoimmune diseases, fibrosis, and infectious diseases by enhancing the precision of drug delivery.
Updated 18 months ago
Funding
$13.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ACFunding rounds are not available yet.
Founders
Product
Features
- The startup develops lipid nanoparticles (LNPs) that specifically target myeloid cells, enabling the direct delivery of therapeutic agents to macrophages and dendritic cells. This technology facilitates the development of treatments for cancer, autoimmune diseases, fibrosis, and infectious diseases by enhancing the precision of drug delivery.